



1



2

Science in vaccine development

A unique approach with 2 vaccine candidates

1 Recombinant-protein vaccine approach

The vaccine antigen is the spike protein which will stimulate the immune system to produce antibodies to fight against the virus if the body becomes infected.

2 mRNA vaccine approach

The vaccine stimulates the body cells to produce the spike protein themselves. The immune system will respond to the spike protein by producing antibodies.

MAT-GLB-2004036 v4.0 - 01/2021

3

Sanofi Pasteur and GSK Recombinant Vaccine Candidate Update

Development

- Pre-clinical studies show promising safety and immunogenicity
- Phase 1/2 study show promising immunogenicity
- Phase 2 dose ranging study to enroll in February
- Phase 3 planned to start in May 2021

Capacity & Supply

- Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant
- Collaborative effort with BARDA to supply up to 100 million doses
- Agreement to supply the UK and EU
- GSK and Sanofi plan to supply a significant portion of total worldwide available supply in 2021/2022 to COVAX, the vaccines pillar of the ACT-Accelerator (Access to COVID-19 Tools)

14

4

Sanofi Pasteur and Translate Bio mRNA Vaccine Candidate Update

Development

- Preclinical data shows that two immunizations of the mRNA vaccine induced high neutralizing antibody levels that are comparable to the upper range of those observed in infected humans
- Phase 1/2 study expected to start in March

Capacity & Supply

- Translate Bio has established mRNA manufacturing capacity and Sanofi expects to be able to supply annual capacity of 90 to 360 million doses.

14

5



6